Abstract
Valvular heart diseases are an important cause of cardiovascular morbidity and mortality, especially among older populations and patients with multiple comorbidities. In recent decades, transcatheter therapies have profoundly changed the treatment of aortic stenosis, mitral regurgitation, and tricuspid regurgitation, expanding therapeutic options for patients at high surgical risk or with contraindications to conventional surgery. This systematic review with subgroup-structured meta-analysis aimed to evaluate the effects of transcatheter therapies for valvular heart diseases on left and right ventricular remodeling, as well as their association with clinical outcomes. Thirty studies involving TAVI/TAVR, mitral transcatheter edge-to-edge repair, transcatheter mitral valve replacement, and transcatheter tricuspid interventions were included. Due to the clinical and methodological heterogeneity among the valvular diseases, devices, and populations evaluated, the results were organized by therapeutic subgroups and analyzed through a tabular quantitative synthesis. The findings indicated that TAVI/TAVR presented the most consolidated evidence, being associated with reduced pressure overload, left ventricular reverse remodeling, and improved clinical outcomes across different risk profiles. In mitral therapies, the benefit was more dependent on patient selection, baseline ventricular remodeling, and the proportionality of mitral regurgitation. In tricuspid interventions, improvements in quality of life, reduction of regurgitation, and potential right-sided chamber remodeling were observed, although the effects on mortality still require further confirmation. In conclusion, ventricular remodeling is a relevant marker of therapeutic response and prognosis after transcatheter valve therapies and should be incorporated into clinical, echocardiographic, and methodological assessment in future studies. Keywords: heart valve diseases; transcatheter procedures; ventricular remodeling; meta-analysis.